Immunokey

ImmunoKey is a seed-stage biotechnology company developing CAR T-cell therapies designed to overcome the barriers limiting efficacy in solid tumours.

Its proprietary platform enables multi-antigen targeting while minimising off-tumour toxicity, supported by complementary technologies to enhance T-cell persistence and function within the tumour microenvironment.

The company's initial focus is ovarian cancer, with preclinical proof-of-concept targeted by 2026 and clinical trials to follow. ImmunoKey has received a ScaleReady manufacturing grant to support process development.